1. Home
  2. UHS vs PTGX Comparison

UHS vs PTGX Comparison

Compare UHS & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Universal Health Services Inc.

UHS

Universal Health Services Inc.

N/A

Current Price

$173.09

Market Cap

10.2B

Sector

Health Care

ML Signal

N/A

Logo Protagonist Therapeutics Inc.

PTGX

Protagonist Therapeutics Inc.

N/A

Current Price

$157.34

Market Cap

9.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UHS
PTGX
Founded
1978
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Hospital/Nursing Management
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.2B
9.5B
IPO Year
1994
2016

Fundamental Metrics

Financial Performance
Metric
UHS
PTGX
Price
$173.09
$157.34
Analyst Decision
Buy
Strong Buy
Analyst Count
11
13
Target Price
$216.36
$108.23
AVG Volume (30 Days)
883.7K
470.6K
Earning Date
04-27-2026
05-07-2026
Dividend Yield
0.48%
N/A
EPS Growth
37.34
N/A
EPS
11.63
2.35
Revenue
$17,364,829,000.00
N/A
Revenue This Year
$7.67
$874.25
Revenue Next Year
$4.99
N/A
P/E Ratio
$14.66
$67.50
Revenue Growth
9.71
N/A
52 Week Low
$140.08
$55.26
52 Week High
$246.33
$158.95

Technical Indicators

Market Signals
Indicator
UHS
PTGX
Relative Strength Index (RSI) 64.85 71.61
Support Level $173.79 $94.48
Resistance Level $175.51 N/A
Average True Range (ATR) 5.38 5.13
MACD 0.10 1.22
Stochastic Oscillator 94.67 93.80

Price Performance

Historical Comparison
UHS
PTGX

About UHS Universal Health Services Inc.

Universal Health Services Inc offers healthcare services through its behavioral health centers, acute care hospitals, and related outpatient facilities. As of late 2025, the company operated 346 inpatient behavioral health centers, 29 acute care hospitals, and many supportive outpatient facilities. Its operations are concentrated in the U.S, particularly in Nevada (21% of 2025 operating profits), Texas (19%), and California (13%), although it does have some exposure to the UK behavioral health market (6% of 2025 sales) too. While its acute care services account for over 55% of revenue, the behavioral health centers sport higher margins and account for over 55% of pretax profits.

About PTGX Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.

Share on Social Networks: